Skip to main content

Table 4 Characteristics, measurements and pharmacotherapy of patients in HF stage C at the study visit according to left ventricular ejection fraction

From: Heart failure in patients with coronary heart disease: Prevalence, characteristics and guideline implementation – Results from the German EuroAspire IV cohort

Left ventricular ejection fraction

<40%

40–52%

>52%

p

N (%)

18 (8.4)

43 (20.1)

153 (71.5)

 

Age year, mean (SD)

69 (8.6)

69 (9.3)

67 (9.2)

0.4091

Males, n (%)

17 (94.4)

36 (83.7)

117 (76.5)

0.162

NYHA class, n (%)

   

0.1042

 I

5 (29.4)

9 (21.4)

53 (35.1)

 

 II

5 (29.4)

20 (47.6)

66 (43.7)

 

 III

5 (29.4)

12 (28.6)

30 (19.9)

 

 IV

2 (11.8)

1 (2.4)

2 (1.3)

 

Hs-TnT, median (IQR)

14.3 (8.6–22.9)

12.3 (8.1–17.8)

8.9 (6.7–13.0)

0.0013

NT-proBNP, median (IQR)

783 (371.5–1960.5)

495 (255.5–1061.8)

189 (86.5–401.0)

<0.0013

Beta blocker, n (%)

18 (100)

38 (88.4)

125 (81.7)

0.0852

ACEi/ARB, n (%)

16 (88.9)

36 (83.7)

125 (81.7)

0.8722

MRA, n (%)

3 (16.7)

7 (16.3)

7 (4.6)

0.0112

Loop diuretic, n (%)

12 (66.7)

21 (48.8)

35 (22.9)

<0.0012

Thiazide diuretic, n (%)

2 (11.1)

1 (2.3)

37 (24.2)

0.0012

Glycoside, n (%)

3 (16.7)

4 (9.3)

7 (4.6)

0.0742

  1. N = 225, age 68.1 (9.1) years, males 180 (80%)
  2. NYHA New York Heart Association functional class, hsTNT high sensitive troponin T, NT-proBNP N-terminal pro B-type natriuretic peptide, ACEi/ARB angiotensin-converting-enzyme inhibitor/angiotensin-receptor blocker, MRA mineralocorticoid receptor antagonist, GAI-3 Guideline Adherence Indicator: number of drugs indicated divided by number of drugs prescribed according to 2008 ESC HF guideline [2]
  3. 1ANCOVA
  4. 2Fisher’s exact test
  5. 3Kruskal-Wallis test